1. Academic Validation
  2. Chiral hydroxymethyl-1 H,3 H-pyrrolo[1,2- c]thiazoles: the search for selective p53-activating agents for colorectal cancer therapy

Chiral hydroxymethyl-1 H,3 H-pyrrolo[1,2- c]thiazoles: the search for selective p53-activating agents for colorectal cancer therapy

  • RSC Med Chem. 2024 Apr 12;15(5):1652-1663. doi: 10.1039/d4md00076e.
Mees M Hendrikx 1 Adelino M R Pereira 1 Ana B Pereira 1 Carla S C Carvalho 2 João L P Ribeiro 1 Maria I L Soares 1 Lucília Saraiva 2 Teresa M V D Pinho E Melo 1
Affiliations

Affiliations

  • 1 University of Coimbra, Coimbra Chemistry Centre - Institute of Molecular Sciences and Department of Chemistry 3004-535 Coimbra Portugal tmelo@ci.uc.pt.
  • 2 LAQV/REQUIMTE, Laboratório de Microbiologia, Departamento de Ciências Biológicas, Faculdade de Farmácia, Universidade do Porto Porto Portugal.
Abstract

MANIO is an efficient p53-activating Anticancer agent with remarkable selectivity to the p53 pathway and promising antitumor activity against colorectal Cancer (CRC). Herein, a library of novel MANIO derivatives, including hydroxymethyl- and bis(hydroxymethyl)-1H,3H-pyrrolo[1,2-c]thiazoles, was synthesized by rational structural modulation. The antiproliferative activity of twenty derivatives was evaluated in a panel of human CRC cells with different p53 status. From this library, five compounds with R- and S-configuration and with aromatic or heteroaromatic groups at position 3, including the enantiomer of MANIO, were identified as selective towards p53-expressing Cancer cells. On the Other hand, two compounds with S-configuration, 6-hydroxymethyl- and 7-hydroxymethyl-5-methyl-3-phenyl-1H,3H-pyrrolo[1,2-c]thiazoles, showed high cytotoxicity against WTp53-expressing HCT116 colon cells but, unlike MANIO, exhibited p53-independent inhibitory activity in CRC. The results described provide relevant structural and pharmacophoric data for the design of new p53-activating agents for precision therapy of CRC or Other p53-related cancers harboring both wild-type or mutated p53 forms.

Figures